Developmental funding is used at Lombardi for recruitments, bridge funding, investments in new technology and shared resources, and pilot funding for new research projects. Recruitments are critically important to the success of the Lombardi in building its research and clinical care activities. In addltion, innovative and novel components of shared resources have incubated and thrived with the support of Lombardi development strategic investments. Pilot funding has been used to support junior faculty and novel projects; in the next cycle this funding will seed synergy projects to foster Inter- and intra-programmatic research. Developmental funding has been, and will continue to be, a necessary means for completing these essential functions. As evident in Lombardi's past use of the funds, the Cancer Center strives to allocate the funds in equitable and beneficial ways. Since the last review, CCSG developmental funds were leveraged with $41.9 million in institutional funds to recruit four faculty members in areas of strategic need, provide interim salary and research support to one faculty member, support 13 pilot projects and support four new methodologies in shared resources. Funds are now being requested to support three synergy awards per year, funding of biomarker-rich clinical trials testing new hypotheses, provide seed funding for two new shared resources and then additional technologies for existing shared resources, bridge funding for faculty and one or two faculty recruits per year. A portion of funds will be allocated to junior and senior Investigators in development of collaborative translational, basic, and clinical research pilot projects. Lombardi will continue to supplement CCSG developmental funds with Institutional support. We request $280,000 to fund developmental projects over the next funding year. These funds will be a portion of funds allocated to junior and senior investigators in development of collaborative translational, basic, and clinical research pilot projects. $90,000 of CCSG developmental funds will be used to support three pilot synergy studies at $30,000 each, annually. Fundable studies must be proposed by at least two independent Georgetown University faculty members who propose a meritorious and innovative synergistic research study with high likelihood of providing data to support a grant application, e.g., a multi-PI ROI, program project grant, SPORE and center grant. We intend to employ $60,000 of CCSG funds to establish a Survey Methods Shared Resource (SMSR) and a Translational Science Shared Resource (TSSR). $60,000 of CCSG developmental funding will be directed to support the first year of funding for one new recruit yearly, selected as per strategic planning priorities. $40,000 is requested to support pilot funding for one biomarker-rich clinical trial, and $30,000 is requested to provide bridge funding for a CCSG mission-critical investigator.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-18
Application #
8256569
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
18
Fiscal Year
2011
Total Cost
$98,475
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lee, Shiao-Pieng; Kao, Chen-Yu; Chang, Shun-Cheng et al. (2018) Tissue distribution and subcellular localizations determine in vivo functional relationship among prostasin, matriptase, HAI-1, and HAI-2 in human skin. PLoS One 13:e0192632
Paffhausen, Emily S; Alowais, Yasir; Chao, Cara W et al. (2018) Discovery of a stem-like multipotent cell fate. Am J Stem Cells 7:25-37
Akinyemiju, Tomi F; Demb, Joshua; Izano, Monika A et al. (2018) The association of early life socioeconomic position on breast cancer incidence and mortality: a systematic review. Int J Public Health 63:787-797
Tiek, D M; Rone, J D; Graham, G T et al. (2018) Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma. Sci Rep 8:7222
Furth, Priscilla A (2018) Peroxisome proliferator-activated receptor gamma and BRCA1. Endocr Relat Cancer :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Gusev, Yuriy; Bhuvaneshwar, Krithika; Song, Lei et al. (2018) The REMBRANDT study, a large collection of genomic data from brain cancer patients. Sci Data 5:180158
Oppong, Bridget A; Dash, Chiranjeev; O'Neill, Suzanne et al. (2018) Breast density in multiethnic women presenting for screening mammography. Breast J 24:334-338
Fernandez, Harvey R; Gadre, Shreyas M; Tan, Mingjun et al. (2018) The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ 25:1239-1258
Schmidt, Marcel Oliver; Garman, Khalid Ammar; Lee, Yong Gu et al. (2018) The Role of Fibroblast Growth Factor-Binding Protein 1 in Skin Carcinogenesis and Inflammation. J Invest Dermatol 138:179-188

Showing the most recent 10 out of 1120 publications